Saturna Capital Corp Has $94.06 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Saturna Capital Corp reduced its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 945,482 shares of the company's stock after selling 6,718 shares during the period. Merck & Co., Inc. accounts for approximately 1.3% of Saturna Capital Corp's holdings, making the stock its 29th largest holding. Saturna Capital Corp's holdings in Merck & Co., Inc. were worth $94,057,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in MRK. Swedbank AB raised its stake in Merck & Co., Inc. by 38.6% during the 3rd quarter. Swedbank AB now owns 7,530,111 shares of the company's stock worth $855,119,000 after buying an additional 2,095,694 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Merck & Co., Inc. by 8.9% in the third quarter. Principal Financial Group Inc. now owns 6,355,950 shares of the company's stock worth $721,782,000 after acquiring an additional 518,270 shares in the last quarter. Ashton Thomas Securities LLC raised its position in shares of Merck & Co., Inc. by 7.6% during the third quarter. Ashton Thomas Securities LLC now owns 3,071 shares of the company's stock worth $349,000 after purchasing an additional 217 shares during the period. Versor Investments LP bought a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at about $487,000. Finally, WCM Investment Management LLC lifted its holdings in shares of Merck & Co., Inc. by 329.4% during the 3rd quarter. WCM Investment Management LLC now owns 13,664 shares of the company's stock valued at $1,553,000 after purchasing an additional 10,482 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $94.65 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. The stock's 50 day moving average price is $93.87 and its two-hundred day moving average price is $102.25. The firm has a market capitalization of $239.09 billion, a price-to-earnings ratio of 14.06, a P/E/G ratio of 0.77 and a beta of 0.35. Merck & Co., Inc. has a 12-month low of $81.04 and a 12-month high of $134.63.

Remove Ads

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share for the quarter, missing analysts' consensus estimates of $1.85 by ($0.13). Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The business had revenue of $15.62 billion for the quarter, compared to analyst estimates of $15.51 billion. During the same period in the previous year, the firm posted $0.03 earnings per share. The firm's revenue was up 6.8% compared to the same quarter last year. On average, analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. announced that its Board of Directors has initiated a share buyback plan on Tuesday, January 28th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the company to reacquire up to 4.1% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its stock is undervalued.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be issued a dividend of $0.81 per share. This represents a $3.24 annualized dividend and a dividend yield of 3.42%. The ex-dividend date is Monday, March 17th. Merck & Co., Inc.'s payout ratio is 48.14%.

Insider Buying and Selling

In related news, insider Cristal N. Downing sold 2,361 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $88.76, for a total transaction of $209,562.36. Following the completion of the sale, the insider now directly owns 7,085 shares of the company's stock, valued at approximately $628,864.60. This trade represents a 24.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Inge G. Thulin acquired 2,833 shares of the firm's stock in a transaction on Thursday, February 6th. The stock was purchased at an average cost of $88.25 per share, for a total transaction of $250,012.25. Following the completion of the acquisition, the director now owns 2,933 shares in the company, valued at approximately $258,837.25. This represents a 2,833.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have commented on MRK shares. Leerink Partners dropped their target price on shares of Merck & Co., Inc. from $136.00 to $119.00 and set an "outperform" rating on the stock in a report on Monday, January 13th. Truist Financial reaffirmed a "hold" rating and issued a $110.00 price objective (down from $130.00) on shares of Merck & Co., Inc. in a research report on Wednesday, January 8th. Bank of America reduced their target price on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating for the company in a research note on Wednesday, February 5th. UBS Group dropped their price target on Merck & Co., Inc. from $125.00 to $120.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Finally, Hsbc Global Res raised Merck & Co., Inc. from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, December 4th. Eleven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and a consensus target price of $117.12.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.